Currently out of the existing stock ratings of Benjamin Burnett, 81 are a BUY (62.79%), 47 are a HOLD (36.43%), 1 are a SELL (0.78%).

Benjamin Burnett

Work Performance Price Targets & Ratings Chart

Analyst Benjamin Burnett works at STIFEL with a stock forecast success ratio of 45.58% fulfilled within 68.74 days on average.

Benjamin Burnett’s has documented 253 price targets and ratings displayed on 23 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on KNTE, Kinnate Biopharma at 26-Feb-2024.

Wall Street Analyst Benjamin Burnett

Analyst best performing recommendations are on EFTR (EFFECTOR THERAPEUTICS).
The best stock recommendation documented was for EFTR (EFFECTOR THERAPEUTICS) at 5/26/2023. The price target of $1.3 was fulfilled within 11 days with a profit of $0.64 (96.97%) receiving and performance score of 88.15.

Average potential price target upside

of $36.13 (118.91%) on GBT (GLOBAL BLOOD THERAPEUTICS).
of $14.49 (43.81%) on ACLX (ARCELLX).
of $10.2 (45.04%) on IOVA (IOVANCE BIOTHERAPEUTICS).

ALLO Allogene Therapeutics ATRA Atara Biotherapeutics BLUE Bluebird bio CRSP Crispr Therapeutics AG CTIC CTi Biopharma Corp DTIL Precision BioSciences FATE Fate Therapeutics GBT Global Blood Therapeutics IOVA Iovance Biotherapeutics MRTX Mirati Ther NKTR Nektar Therapeutics SGMO Sangamo Therapeutics PGEN Precigen IDYA Ideaya Biosciences RPTX Repare Therapeutics RVMD Revolution Medicines EFTR Effector Therapeutics GNCA Genocea Biosciences NLTX Neoleukin Therapeutics BEAM Beam Therapeutics KNTE Kinnate Biopharma ACLX Arcellx GRCL Gracell Biotechnologies .

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Brian Cheng (JPMORGAN)